Aug 1 (Reuters) - German Chemicals Group Evonik Industries Evkn.de on Thursday Said It Expected Its Core Profit for the Third Quarter to Be "on Par" With That of the Second Quarter.
8月1日(路透社)-德國化學集團Evonik Industries表示,預計第三季度的核心利潤與第二季度"相當"。 Evkn.de 這家專業化學制造商表示,在第二季度調整後的利息、稅項、折舊和攤銷前利潤(Ebitda)爲57800萬歐元(62600萬美元),與7月公佈的初步數據保持一致。
The Speciality Chemicals Maker Said Its Second-Quarter Adjusted Earnings Before Interest, Tax, Depreciation and Amortisation (Ebitda) Was 578 Million Euros ($626 Million), in Line With the Preliminary Figure Published in July.
這家專業化學品製造商表示,其第二季度的調整後利潤、稅項、折舊和攤銷前利潤(Ebitda)爲57800萬歐元(62600萬美元),與7月公佈的初步數據保持一致。 初步數字。 Evonik,這家化學品公司的產品被汽車和動物飼料到輝瑞和biontech的covid疫苗使用,確認其年調整後Ebitda在19億至22億歐元之間的前景,這是該公司上個月宣佈的。
Evonik, Whose Chemicals Are Used in Products From Autos and Animal Feed to Pfizer and BioNTech's Covid Vaccine, Confirmed Its Annual Outlook for an Adjusted Ebitda of Between 1.9 Billion and 2.2 Billion Euros, Which It Raised Last Month.
上個月宣佈的。 募資額 這家化學品公司的產品被汽車和動物飼料到輝瑞和biontech的covid疫苗使用,確認其年調整後Ebitda在19億至22億歐元之間的前景,這是該公司上個月宣佈的。
The Outlook for Its Other Key Financial Figures Also Remains Unchanged, Evonik Added.
Evonik還表示,其他關鍵財務數據的前景也保持不變。
"We Are Headed in the Right Direction, and the Improvements in Our Key Financial Figures Compared to the Previous Year Are Really Encouraging," Chief Financial Officer Maike Schuh Said in a Statement.
"我們正在朝着正確的方向前進,與去年相比,我們關鍵的財務數據的改善真正令人鼓舞,"首席財務官Maike Schuh在一份聲明中說。
"However, the Current Recovery Compares to a Very Weak 2023, and We Are Still a Long Way From Reaching Our Goals," Schuh Added.
"然而,目前的復甦與一個非常薄弱的2023年相比,我們離達成目標還有很長的路要走,"Schuh補充說。
The Company Said It Expected the Sale of Its Superabsorbents Business to Be Completed During the Third Quarter.
該公司表示,預計其高吸水性業務的收購將在第三季度完成。 出售 該公司表示,預計其高吸水性業務的收購將在第三季度完成。
($1 = 0.9232 Euros)
($1 = 0.9232歐元)
(Reporting by Anastasiia Kozlova and Amir Orusov in Gdansk; Editing by Milla Nissi)
(彙報:Anastasiia Kozlova和Amir Orusov在格但斯克; Milla Nissi編輯)